期刊
PEDIATRIC BLOOD & CANCER
卷 52, 期 5, 页码 664-666出版社
WILEY-LISS
DOI: 10.1002/pbc.21808
关键词
ataxia-telangiectasia; CHOP; CVID; NHL; rituximab
Children with primary immunodeficiency or chromosomal breakage syndromes are at increased risk of developing non-Hodgkin lymphomas; they cannot tolerate standard chemotherapy regimens. We report two children with diffuse, large, B-cell lymphoma; one had ataxia telangiectasia and one had common variable immunodeficiency. Both were given rituximab, 1 as monotherapy and 1 in combination with a reduced CHOP regimen, Complete remission was obtained in each patient. Use of rituximab as a first-line monotherapy or in Conjunction with reduced chemotherapy should be considered to reduce cytotoxic effects. Pediatr Blood Cancer 2009;52:664-666. (C) 2009 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据